Sanofi CEO: Making drug data public could hurt investment in EU

06/24/2013 | Reuters

The European Medicines Agency's publication of a draft policy that would make detailed data on drugs publicly available after they are approved could deter crucial investment in Europe, said Chris Viehbacher, CEO of Sanofi and president of the European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Research and Manufacturers of America has condemned EMA's plans to unveil clinical-trial information, saying it could weaken research incentives and harm business.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY